Treatment of prostate cancer cell lines with CDDO-Me and CDDO-Im inhibited growth due to the elevated activity of Death receptor 4 (DR4) and DR5, which serve as surfaces for TRAIL (Hyer et al. 2008). The gene discussed is TNFRSF10A; the disease is prostate carcinoma.